News 26 Mar 2024 Top Stories from Western Switzerland (March 2024) From innovative approaches in cardiac care and sustainable plastics to enhancing spinal cord injury therapies and advancing virtual power plants,...
Actualités 17 Apr 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
News 10 Gen 2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
News 19 Dic 2023 Top Stories from Western Switzerland (October-December 2023) From achieving top rankings in global innovation to making significant advancements in healthcare and technology, discover Western Switzerland's ...
News 10 Mag 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...
Actualités 14 Ago 2023 L’écosystème florissant de Berne pour l’innovation en sciences de la vie Au cœur de la Suisse occidentale, le canton de Berne s'est imposé comme une destination de choix pour les entreprises du secteur des sciences de ...
News 10 Mag 2022 Michael J. Fox Foundation awards Asceneuron a grant to treat Parkinson’s disease Committed to accelerating research into novel Parkinson’s Disease therapies, The Michael J. Fox Foundation for Parkinson’s Research is again awar...
News 17 Apr 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
Aktuell 06 Giu 2023 Novocure spendet 3 Millionen Dollar für Krebsforschung Das Onkologieunternehmen Novocure wird Conquer Cancer über drei Jahre mit jeweils 1 Million Dollar unterstützen. Die Mittel sollen von der Stiftu...
Aktuell 22 Gen 2024 DISCO Pharmaceuticals startet mit 20 Millionen Euro Kapital DISCO Pharmaceuticals ist mit einem Startkapital von 20 Millionen Euro neu auf dem Markt. Sein Team hat als erstes eine Methode entwickelt, die e...
News 29 Set 2023 Top Stories from Western Switzerland (July-September 2023) From spearheading eco-innovative solutions to pioneering breakthroughs in solar technology, cancer research, sustainable shipping, and the realms...
News 18 Ott 2023 BioArk Monthey’s third building signifies exponential growth in the life sciences sector With two decades under its belt, the BioArk site in Monthey continues to cement its position as a front-runner in life sciences.
News 24 Ago 2023 Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking Drawing from the achievements of its parent company, Nanobacterie, Valais-based AlphaOnco Swiss stands at the forefront of innovative nanomedicin...
News 03 Apr 2024 Nouscom receives additional funding for cancer vaccines Nouscom has received an investment totalling 7 million euros from the Italian venture capital firm Angelini Ventures. The Basel-based biotech com...
News 07 Ago 2023 Longevity start-up EPITERNA raises EUR 10 million to slow ageing and extend lifespan Vaud-based longevity start-up EPITERNA has secured EUR 10 million in funding from Prima Materia, an investment firm founded by Spotify founder Da...
News 06 Giu 2023 Novocure to donate 3 million US dollars to cancer research Novocure, a biotechnology firm specializing in the field of oncology, has pledged support of 1 million US dollars per year for a period of three ...
News 16 Ott 2023 Adiposs completes the phase I clinical trial of its flagship product ImageBAT Geneva-based biotech Adiposs casts a ray of hope onto the horizons of cancer treatment and patient care with the successful conclusion of the Pha...
News 14 Ago 2023 Bern’s thriving ecosystem for life sciences innovation In the heart of Western Switzerland, the canton of Bern has emerged as a location of choice for companies in the life sciences sector.